Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Bioshares Conference July 2024
20 slides from Island Pharmaceuticals's conference presentation, Jul 1, 2024
Slide 1: Addressing Urgent Viral Disease and Medical Countermeasures Threats
ADDRESSING URGENT VIRAL DISEASE AND MEDICAL COUNTERMEASURES THREATS DR PAUL MACLEMAN, EXECUTIVE CHAIR (ASX: ILA) BIOSHARES CONFERENCE | JULY 2024 ISLAND PHARMACEUTICALS 1 JULY 2024
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financial product advice "esti
Slide 3: Addressing Urgent Viral Disease and Medical Countermeasures Threats: Assets
ADDRESSING URGENT VIRAL DISEASE AND AND MEDICAL COUNTERMEASURES THREATS ASSETS Known small molecules with clinical history Mid/late stage clinical or other abbreviated routes Open USFDA INDs Validated US Govt/military funding support Priority Review Voucher eligible RAPID PATHS TO MARKET (ASX: ILA)
Slide 4: Strategic Checklist
STRATEGIC CHECKLIST Clinical history Small molecule Proven preclinical anti-viral activity Eligible for Priority Review Vouchers National and military preparedness need Probable/confirmed non-dilutive funding to support: military, civilian, NGO Fit for our management and advisory team:
Slide 5: Strategic Connectivity Between Assets ISLA101 and Galidesivir
STRATEGIC CONNECTIVITY BETWEEN ASSETS ISLA101 (FENRETINIDE) AND GALIDESIVIR Both assets are: • Phase II or later • Have open Investigational New Drug applications with FDA • Antivirals, therefore fast to develop and potential for early licensing if sought • Supported by governments and military; nee
Slide 6: About ISLA-101
About ISLA-101 ISLAND PHARMACEUTICALS 6 JULY 2024
Slide 7: About half of the world's population is now at risk of dengue
“About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 30 May 2024 ISLAND PHARMACEUTICALS 7 JULY 2024
Slide 8: Targeting Known or Re-purposable Drugs with Reduced Time to Market
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET ISLA-101 – dengue, Zika, Yellow Fever, Chikungunya, other arboviruses • 45+ human trials of ISLA-101 completed in other indications • Island’s recent SAD study reinforced safety and established the effective human EC50 dose • Infecti
Slide 9: Dengue Is Close to Home
DENGUE IS CLOSE TO HOME Source 1 Source 2 Source 3 Source 4 (Described as potential super-spreader event) Article sources: 1. https://www.news.com.au/travel/travel-updates/travel-stories/deadly-viral-infection-doubles-in-popular-tourists-spots- for-aussies/news-story/fc32fa4fc37ee1ed4ca48a4deb44f51c
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE WHO prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.gov/features/disea
Slide 11: US Army CRADA Provides Control Group for Phase II Study
US ARMY CRADA PROVIDES CONTROL GROUP FOR PHASE II STUDY (AND SUBSTANTIAL % OF PHASE II TRIAL COSTS) P1 challenge study conducted by Walter Reed Army Institute of Research and SUNY is ILA’s P2 study control data, and enables unprecedented ability to monitor dengue symptoms, including: • Abdominal & e
Slide 12: Galidesivir: Targeting Known or Re-purposable Drugs
TARGETING KNOWN OR RE-PURPOSABLE DRUGS WITH REDUCED TIME TO MARKET GALIDESIVIR – Ebola, Marburg, Zika & and most other RNA viruses • 12 month, non-binding term sheet signed 3 July 2024 (AU) • Phase I human safety data • Proven protective efficacy in a number of lethal animal models • If proceed to f
Slide 13: Commercial Opportunities
COMMERCIAL OPPORTUNITIES BOTH candidates have prophylactic and therapeutic potential Travelers Military National Outbreaks Malaria is also a mosquito Relationship with US Army in Millions of patients in Latin borne disease and therefore a place (CRADA, ISLA101). Will America & Asia offer potential p
Slide 14: Corporate Snapshot
CORPORATE SNAPSHOT Key data Recent ILA trading history Share price (AUD1) $0.066 Market cap1 $8.37m Shares on issue1 126,767,093 Listed Options2 32,506,360 Cash3 $1.6m Board of Directors Substantial shareholders Ownership breakdown Dr Paul MacLeman, Executive Chairman Shareholder Ownership4 • Top 20
Slide 15: Upcoming Milestones
UPCOMING MILESTONES** H1 FY 2024 (Jul – Dec 2023) H2 FY 2024 (Jan – Jun 2024) H1 FY 2025 (Jul – Dec 2024) H2 FY 2025 (Jan – Jun 2025) • Key US and Australian • Dose final Single • Obtain ethics • Data readout from patents granted for ISLA- Ascending Dose approval for Phase 2 Phase 2 study 101 study
Slide 16: Island Pharmaceuticals (ASX: ILA)
Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals [email protected] +61 419 401 445 ISLAND PHARMACEUTICALS 16 JULY 2024
Slide 17: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the US WRAIR – SUNY Upstate BMS – Mayo Clinic biotechnology and pharmaceutical industry and is Professor Stephen Thomas, MD has an international Amy Patick is a scientific consultan
Slide 18: ISLA-101 Prevents Viral Replication
ISLA-101 PREVENTS VIRAL REPLICATION Mechanism of action (how it works) ISLA-101 reduces viral load1 ISLA-101 inhibits propagation of flaviviruses Above: dose response showing ISLA-101’s ability to protect against dengue infection • To replicate, the virus needs to hijack the nucleus of the host cell
Slide 19: Galidesivir Prevents Viral Replication
GALIDESIVIR PREVENTS VIRAL REPLICATION Galidesivir inhibits propagation of RNA viruses • RNA-dependent RNA polymerase (RdRp) is crucial in viral replication and transcription • Catalyses viral RNA synthesis and is the therapeutic target of Galidesivir https://link.springer.com/article/10.1007/s41061
Slide 20: Players in the Medical Countermeasures Space
PLAYERS IN THE MEDICAL COUNTERMEASURES SPACE Programs backed by BARDA and/or NIAID • BioFactura • BioFire Defense • Certara • Emergent BioSolutions • Evotec SE • IDbyDNA (DIGET program) • Juxtopia • DARPA Panacea Program • ARMR • JnJ Blue Knight Consortium https://globalbiodefense.com ISLAND PHARMAC
Island Pharmaceuticals — Bioshares Conference July 2024 on 6ix